28 / 48
Peters NEJM 2017
ALEX phase 3 study:
Primary endpoint PFS (IRF)
NR
11.1 mo
Time, months
0
6
12
18
27
100
80
60
40
20
0
24
21
3
9
15
1
NR
PFS probability, %
J-ALEX phase 3 study:
Primary endpoint PFS (IRF)
Hida S, Lancet 2017
HR 0.34 (CI 0.17, 0.71)
p<0.0001
HR 0.47 (CI 0.34, 0.65)
p< 0.001
NR
10.2 mo
Alectinib
Crizotinib
N Engl J Med 2017;377:829-38.